Competitive Analysis: Leading Companies and New Entrants in the Prescription Drugs Market

The prescription drugs sector is on the verge of substantial expansion, driven by multiple evolving factors shaping its future. As demand patterns shift and new technologies emerge, this market is set to undergo significant transformation in the coming years. Here's an in-depth look at its projected size, key industry players, prevailing trends, and distinct market segments.

Projected Growth and Size of the Prescription Drugs Market by 2030
The prescription drugs market is anticipated to experience rapid growth, reaching a valuation of $2368.39 billion by 2030. This surge corresponds to a compound annual growth rate (CAGR) of 10.5%. Several elements are fueling this expansion, such as the increasing popularity of affordable generic medications, wider acceptance of biosimilars, the growth in digital platforms for prescriptions, a stronger emphasis on personalized drug treatments, and enhanced regulatory harmonization across various regions. Important trends expected to influence this market include the growing use of specialty prescription drugs, a rise in demand for generic alternatives, a greater focus on managing chronic illnesses, the expansion of biologic and biosimilar treatments, and stricter regulatory oversight regarding drug safety.

Download a free sample of the prescription drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20597&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Influencing the Prescription Drugs Market
The market is dominated by several key pharmaceutical giants including Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, and Lupin Limited.

Significant Acquisition Strengthening Neuroscience Portfolio
In December 2023, Bristol Myers Squibb, the US-based pharmaceutical firm, completed a $14 billion acquisition of Karuna Therapeutics. This strategic move aims to bolster Bristol Myers Squibb's neuroscience offerings by incorporating Karuna's innovative cholinergic-based treatments, such as KarXT, and broadening its pipeline for conditions like schizophrenia and Alzheimer's disease psychosis. Karuna Therapeutics specializes in prescription drugs targeting neuroscience disorders and is also headquartered in the United States.

View the full prescription drugs market report:
https://www.thebusinessresearchcompany.com/report/prescription-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Impacting the Prescription Drugs Industry
A notable development in the prescription drugs market is the focus on creating alternatives to Victoza (liraglutide), a popular GLP-1 receptor agonist used for treating type 2 diabetes. Victoza helps manage this condition in adults and children aged 10 and above by regulating blood sugar levels effectively. In June 2024, Israel-based Teva launched an authorized generic version of Victoza (1.8 mg liraglutide injection). This product offers the same formulation, quality, and efficacy as the original while being more affordable. The introduction of such generics aims to improve patient access to critical diabetes treatments, providing cost-effective options that also help mitigate cardiovascular risks linked to diabetes.

Market Segmentation and Share in the Global Prescription Drugs Industry
This report segments the prescription drugs market into various categories for a detailed understanding:
1) By Type: Branded drugs and generics
2) By Route of Administration: Oral, topical, parenteral, and other methods
3) By Therapy Area: Including oncology, immunology, ophthalmology, respiratory, dermatology, gastroenterology, urology, gynecology, endocrinology, and other therapeutic segments
4) By End-Users: Hospitals, specialty clinics, homecare settings, and other users

Further subcategories include:
- For branded drugs: innovative, patented, blockbuster, OTC prescription, biosimilars, specialty, orphan, and combination drugs
- For generics: small molecule generics, generic biologics, OTC generics, authorized generics, generic combination drugs, high-volume generics, and generic versions of blockbuster drugs

This detailed classification offers a comprehensive view of the prescription drugs market's complexity and diversity, illustrating the wide range of products and applications within this growing industry.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.